Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.

Gold R, Radue E-W, Giovannoni G, Selmaj K, Havrdova E, Stefoski D, Sprenger T, Montalban X, Cohan S, Umans K, et al.

BMC Neurol. 2016; 16:117. Epub 2016 Jul 26. PMID: 27461166. Abstract